DK1622908T3 - Xanthin-derivater som A2B adenosin-receptor-antagonister - Google Patents

Xanthin-derivater som A2B adenosin-receptor-antagonister

Info

Publication number
DK1622908T3
DK1622908T3 DK03817096T DK03817096T DK1622908T3 DK 1622908 T3 DK1622908 T3 DK 1622908T3 DK 03817096 T DK03817096 T DK 03817096T DK 03817096 T DK03817096 T DK 03817096T DK 1622908 T3 DK1622908 T3 DK 1622908T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
adenosine receptor
xanthine derivatives
xanthine
derivatives
Prior art date
Application number
DK03817096T
Other languages
Danish (da)
English (en)
Inventor
Rao Kalla
Thao Perry
Elfatih Elzein
Vaibhav Varkhedkar
Xiaofen Li
Prabha Ibrahim
Venkata Palle
Dengming Xiao
Jeff Zablocki
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1622908T3 publication Critical patent/DK1622908T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK03817096T 2003-05-06 2003-05-06 Xanthin-derivater som A2B adenosin-receptor-antagonister DK1622908T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/014085 WO2004106337A1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
DK1622908T3 true DK1622908T3 (da) 2008-11-17

Family

ID=33488737

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03817096T DK1622908T3 (da) 2003-05-06 2003-05-06 Xanthin-derivater som A2B adenosin-receptor-antagonister

Country Status (16)

Country Link
EP (1) EP1622908B1 (pt)
JP (1) JP2006515316A (pt)
CN (1) CN100590125C (pt)
AT (1) ATE403656T1 (pt)
AU (1) AU2003249604B2 (pt)
CA (1) CA2524778C (pt)
CY (1) CY1108457T1 (pt)
DE (1) DE60322748D1 (pt)
DK (1) DK1622908T3 (pt)
ES (1) ES2311759T3 (pt)
HK (1) HK1092137A1 (pt)
MX (1) MXPA05011860A (pt)
NZ (1) NZ543416A (pt)
PT (1) PT1622908E (pt)
SI (1) SI1622908T1 (pt)
WO (1) WO2004106337A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198608B (zh) * 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
JP2009528389A (ja) * 2006-03-02 2009-08-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシン受容体拮抗剤
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
WO2009118759A2 (en) 2008-03-26 2009-10-01 Advinus Therapeutics Pvt. Ltd., Heterocyclic compounds as adenosine receptor antagonist
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
EP2405917B1 (en) 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
WO2012035548A1 (en) 2010-09-13 2012-03-22 Advinus Therapeutics Private Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
US9359359B2 (en) * 2013-03-15 2016-06-07 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
PL3618829T3 (pl) * 2017-05-05 2023-11-20 Arcus Biosciences, Inc. Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem
SG11202008611UA (en) * 2018-03-05 2020-10-29 Teon Therapeutics Inc Adenosine receptor antagonists and uses thereof
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
CN118459463B (zh) * 2024-07-10 2024-09-06 山东中医药大学附属医院 一种化合物及其制备方法和治疗2型糖尿病的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
DE69812070T2 (de) * 1998-04-24 2003-12-11 K.U. Leuven Research & Development, Leuven Immununterdrückende Effekte von 8 substituierten Xanthinderivaten
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
ATE307132T1 (de) * 2001-06-29 2005-11-15 Cv Therapeutics Inc Purin derivate als a2b adenosin rezeptor antagonisten
PL370207A1 (en) * 2001-11-09 2005-05-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
US7205403B2 (en) * 2002-02-01 2007-04-17 King Pharmaceuticals Research And Development, Inc. 8-Heteroaryl xanthine adenosine A2B receptor antagonists

Also Published As

Publication number Publication date
EP1622908A1 (en) 2006-02-08
CA2524778C (en) 2013-01-29
AU2003249604A1 (en) 2005-01-21
DE60322748D1 (de) 2008-09-18
HK1092137A1 (en) 2007-02-02
AU2003249604B2 (en) 2011-06-30
NZ543416A (en) 2009-01-31
ATE403656T1 (de) 2008-08-15
ES2311759T3 (es) 2009-02-16
CN1771250A (zh) 2006-05-10
JP2006515316A (ja) 2006-05-25
CN100590125C (zh) 2010-02-17
SI1622908T1 (sl) 2008-12-31
CA2524778A1 (en) 2004-12-09
EP1622908B1 (en) 2008-08-06
PT1622908E (pt) 2008-11-14
WO2004106337A1 (en) 2004-12-09
CY1108457T1 (el) 2014-04-09
MXPA05011860A (es) 2006-02-17

Similar Documents

Publication Publication Date Title
HK1092137A1 (en) Xanthine derivatives as a2b adenosine receptor antagonists
WO2003042214A3 (en) A2b adenosine receptor antagonists
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
DK2272517T3 (da) Orto-kondenserede pyridin- og pyrimidinderivater (f.eks. puriner) som proteinkinaseinhibitorer
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
ZA200705040B (en) 2,4 (4,6) pyrimidine derivatives
DK2270008T3 (da) 8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-oner som PI-3-kinaseinhibitorer
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
AP2005003452A0 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
IS7534A (is) Pýrazóló-pýrimídín anilín efnasambönd, gagnleg sem kínasatálmar
DE50210707D1 (de) Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
NO20053600D0 (no) Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
ATE387446T1 (de) Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
WO2005105803A3 (en) Purine derivatives as a1 adenosine receptor antagonists
ATE452892T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
DK1608653T3 (da) Substituerede 8-perfluoroalkyl-6,7,8,9- tetrahydropyrimido (1,2-a) pyrimidin-4-on derivater
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
ATE358130T1 (de) Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
NO20053335D0 (no) 2-aminokarbonyl-kinolinforbindelser som blodplateadenosindifosfatreseptorer.
DK1534707T3 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
BR0309053A (pt) Compostos